journal
MENU ▼
Read by QxMD icon Read
search

Lancet Oncology

journal
https://www.readbyqxmd.com/read/30416077/genomically-annotated-risk-model-for-advanced-renal-cell-carcinoma-a-retrospective-cohort-study
#1
Martin H Voss, Albert Reising, Yuan Cheng, Parul Patel, Mahtab Marker, Fengshen Kuo, Timothy A Chan, Toni K Choueiri, James J Hsieh, A Ari Hakimi, Robert J Motzer
BACKGROUND: The Memorial Sloan Kettering Cancer Center (MSKCC) risk model is an established prognostic tool for metastatic renal-cell carcinoma that integrates clinical and laboratory data, but is agnostic to tumour genomics. Several mutations, including BAP1 and PBRM1, have prognostic value in renal-cell carcinoma. Using two independent clinical trial datasets of patients with metastatic renal-cell carcinoma, we aimed to study whether the addition of the mutation status for several candidate prognostic genes to the MSKCC model could improve the model's prognostic performance...
November 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30416076/temporal-patterns-in-the-risk-of-chronic-health-conditions-in-survivors-of-childhood-cancer-diagnosed-1970-99-a-report-from-the-childhood-cancer-survivor-study-cohort
#2
Todd M Gibson, Sogol Mostoufi-Moab, Kayla L Stratton, Wendy M Leisenring, Dana Barnea, Eric J Chow, Sarah S Donaldson, Rebecca M Howell, Melissa M Hudson, Anita Mahajan, Paul C Nathan, Kirsten K Ness, Charles A Sklar, Emily S Tonorezos, Christopher B Weldon, Elizabeth M Wells, Yutaka Yasui, Gregory T Armstrong, Leslie L Robison, Kevin C Oeffinger
BACKGROUND: Treatments for childhood cancer have evolved over the past 50 years, with the goal of maximising the proportion of patients who achieve long-term survival, while minimising the adverse effects of therapy. We aimed to assess incidence patterns of serious chronic health conditions in long-term survivors of childhood cancer across three decades of diagnosis and treatment. METHODS: We used data from the Childhood Cancer Survivor Study, a retrospective cohort with longitudinal follow-up of 5-year survivors of common childhood cancers (leukaemia, tumours of the CNS, Hodgkin lymphoma, non-Hodgkin lymphoma, Wilms tumour, neuroblastoma, soft tissue sarcoma, or bone tumours) who were diagnosed before the age of 21 years and from 1970 to 1999 in North America...
November 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30416075/long-term-follow-up-care-needed-for-children-surviving-cancer-still-a-long-way-to-go
#3
Jeanette F Winther, Leontien Kremer
No abstract text is available yet for this article.
November 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30416074/biomarkers-in-renal-cell-carcinoma-building-on-clinical-paradigms
#4
Neeraj Agarwal, Roberto Nussenzveig, Sumanta K Pal
No abstract text is available yet for this article.
November 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30416073/outcomes-after-minimally-invasive-surgery-in-cervical-cancer
#5
Talha Khan Burki
No abstract text is available yet for this article.
November 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30413383/neoadjuvant-chemotherapy-versus-debulking-surgery-in-advanced-tubo-ovarian-cancers-pooled-analysis-of-individual-patient-data-from-the-eortc-55971-and-chorus-trials
#6
Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh K B Parmar, Tom Ehlen, Gordon C Jayson, Nick Johnson, Ann Marie Swart, René Verheijen, W Glenn McCluggage, Tim Perren, Pierluigi Benedetti Panici, Gemma Kenter, Antonio Casado, Cesar Mendiola, Gavin Stuart, Nick S Reed, Sean Kehoe
BACKGROUND: Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any preferable therapeutic approaches for subgroup populations. METHODS: We did a per-protocol pooled analysis of individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 55971 trial (NCT00003636) and the Medical Research Council Chemotherapy Or Upfront Surgery (CHORUS) trial (ISRCTN74802813)...
November 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30413382/neoadjuvant-chemotherapy-versus-upfront-debulking-surgery-in-advanced-tubo-ovarian-cancer
#7
Anna Fagotti, Giovanni Scambia
No abstract text is available yet for this article.
November 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30413381/lorlatinib-a-new-generation-drug-for-alk-positive-nsclc
#8
Saiama N Waqar, Daniel Morgensztern
No abstract text is available yet for this article.
November 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30413380/fine-tuning-chemotherapy-in-the-era-of-dual-her2-targeting
#9
Sherene Loi
No abstract text is available yet for this article.
November 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30413379/neoadjuvant-chemotherapy-with-or-without-anthracyclines-in-the-presence-of-dual-her2-blockade-for-her2-positive-breast-cancer-train-2-a-multicentre-open-label-randomised-phase-3-trial
#10
Mette S van Ramshorst, Anna van der Voort, Erik D van Werkhoven, Ingrid A Mandjes, Inge Kemper, Vincent O Dezentjé, Irma M Oving, Aafke H Honkoop, Lidwine W Tick, Agnes J van de Wouw, Caroline M Mandigers, Laurence J van Warmerdam, Jelle Wesseling, Marie-Jeanne T Vrancken Peeters, Sabine C Linn, Gabe S Sonke
BACKGROUND: The optimal chemotherapy backbone for dual HER2 blockade in the neoadjuvant setting for early breast cancer is unknown. We investigated whether the addition of anthracyclines would improve pathological complete response compared with a carboplatin-taxane regimen, when given in combination with the HER2-targeted agents trastuzumab and pertuzumab. METHODS: The TRAIN-2 study is an open-label, randomised, controlled, phase 3 trial being done in 37 hospitals in the Netherlands...
November 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30413378/lorlatinib-in-patients-with-alk-positive-non-small-cell-lung-cancer-results-from-a-global-phase-2-study
#11
Benjamin J Solomon, Benjamin Besse, Todd M Bauer, Enriqueta Felip, Ross A Soo, D Ross Camidge, Rita Chiari, Alessandra Bearz, Chia-Chi Lin, Shirish M Gadgeel, Gregory J Riely, Eng Huat Tan, Takashi Seto, Leonard P James, Jill S Clancy, Antonello Abbattista, Jean-François Martini, Joseph Chen, Gerson Peltz, Holger Thurm, Sai-Hong Ignatius Ou, Alice T Shaw
BACKGROUND: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of ALK and ROS1 tyrosine kinases with broad coverage of ALK mutations. In a phase 1 study, activity was seen in patients with ALK-positive non-small-cell lung cancer, most of whom had CNS metastases and progression after ALK-directed therapy. We aimed to analyse the overall and intracranial antitumour activity of lorlatinib in patients with ALK-positive, advanced non-small-cell lung cancer. METHODS: In this phase 2 study, patients with histologically or cytologically ALK-positive or ROS1-positive, advanced, non-small-cell lung cancer, with or without CNS metastases, with an Eastern Cooperative Oncology Group performance status of 0, 1, or 2, and adequate end-organ function were eligible...
November 6, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30392813/prognostic-effect-of-whole-chromosomal-aberration-signatures-in-standard-risk-non-wnt-non-shh-medulloblastoma-a-retrospective-molecular-analysis-of-the-hit-siop-pnet-4-trial
#12
Tobias Goschzik, Edward C Schwalbe, Debbie Hicks, Amanda Smith, Anja Zur Muehlen, Dominique Figarella-Branger, François Doz, Stefan Rutkowski, Birgitta Lannering, Torsten Pietsch, Steven C Clifford
BACKGROUND: Most children with medulloblastoma fall within the standard-risk clinical disease group defined by absence of high-risk features (metastatic disease, large-cell/anaplastic histology, and MYC amplification), which includes 50-60% of patients and has a 5-year event-free survival of 75-85%. Within standard-risk medulloblastoma, patients in the WNT subgroup are established as having a favourable prognosis; however, outcome prediction for the remaining majority of patients is imprecise...
November 1, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30392812/interrogating-molecular-data-for-medulloblastoma-risk-stratification
#13
Elisabetta Ferretti, Agnese Po
No abstract text is available yet for this article.
November 1, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30392811/promising-new-treatment-for-multiple-myeloma
#14
Elizabeth Gourd
No abstract text is available yet for this article.
November 1, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30392810/age-at-last-screening-and-remaining-lifetime-risk-of-cervical-cancer-in-older-unvaccinated-hpv-negative-women-a-modelling-study
#15
Talía Malagón, Shalini Kulasingam, Marie-Hélène Mayrand, Gina Ogilvie, Leah Smith, Céline Bouchard, Walter Gotlieb, Eduardo L Franco
BACKGROUND: There is a paucity of empirical evidence to inform the age at which to stop cervical cancer screening. The recommended age to stop screening generally varies between age 50-70 years worldwide. However, cervical cancer incidence and mortality remain high in older women. We used a Markov model of cervical cancer screening to estimate the remaining lifetime risk of cervical cancer at different ages and with different exit screening tests, with the aim of informing recommendations of the age at which to stop cervical cancer screening in developed countries...
November 1, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30392809/venetoclax-with-decitabine-or-azacitidine-for-aml
#16
Manjulika Das
No abstract text is available yet for this article.
November 1, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30392808/evidence-based-screening-protocols-for-cervical-cancer
#17
Paolo Giorgi Rossi
No abstract text is available yet for this article.
November 1, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30392807/carcinogenicity-of-some-nitrobenzenes-and-other-industrial-chemicals
#18
(no author information available yet)
No abstract text is available yet for this article.
November 1, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30361171/long-term-survival-with-anti-pd-1-based-immunotherapy-but-what-is-the-best-approach
#19
Mark R Middleton
No abstract text is available yet for this article.
October 18, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30361170/nivolumab-plus-ipilimumab-or-nivolumab-alone-versus-ipilimumab-alone-in-advanced-melanoma-checkmate-067-4-year-outcomes-of-a-multicentre-randomised-phase-3-trial
#20
Frank Stephen Hodi, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Charles Lance Cowey, Christopher D Lao, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Andrew Hill, David Hogg, Ivan Marquez-Rodas, Joel Jiang, Jasmine Rizzo, James Larkin, Jedd D Wolchok
BACKGROUND: Previously reported results from the phase 3 CheckMate 067 trial showed a significant improvement in objective responses, progression-free survival, and overall survival with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab alone in patients with advanced melanoma. The aim of this report is to provide 4-year updated efficacy and safety data from this study. METHODS: In this phase 3 trial, eligible patients were aged 18 years or older with previously untreated, unresectable, stage III or stage IV melanoma, known BRAFV600 mutation status, and an Eastern Cooperative Oncology Group performance status of 0 or 1...
October 18, 2018: Lancet Oncology
journal
journal
20189
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"